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Background: TRAF3, a new tumor suppressor identified in human non-Hodgkin lymphoma (NHL) and multiple
myeloma (MM), induces PKCδ nuclear translocation in B cells. The present study aimed to evaluate the therapeutic
potential of two PKCδ activators, N-Benzyladriamycin-14-valerate (AD 198) and ingenol-3-angelate (PEP005), on NHL
and MM.
Methods: In vitro anti-tumor activities of AD 198 and PEP005 were determined using TRAF3−/− mouse B lymphoma
and human patient-derived MM cell lines as model systems. In vivo therapeutic effects of AD 198 were assessed
using NOD SCID mice transplanted with TRAF3−/− mouse B lymphoma cells. Biochemical studies were performed to
investigate signaling mechanisms induced by AD 198 or PEP005, including subcellular translocation of PKCδ.
Results: We found that AD 198 exhibited potent in vitro and in vivo anti-tumor activity on TRAF3−/− tumor B cells,
while PEP005 displayed contradictory anti- or pro-tumor activities on different cell lines. Detailed mechanistic
investigation revealed that AD 198 did not affect PKCδ nuclear translocation, but strikingly suppressed c-Myc
expression and inhibited the phosphorylation of ERK, p38 and JNK in TRAF3−/− tumor B cells. In contrast, PEP005
activated multiple signaling pathways in these cells, including PKCδ, PKCα, PKCε, NF-κB1, ERK, JNK, and Akt.
Additionally, AD198 also potently inhibited the proliferation/survival and suppressed c-Myc expression in TRAF3-
sufficient mouse and human B lymphoma cell lines. Furthermore, we found that reconstitution of c-Myc expression
conferred partial resistance to the anti-proliferative/apoptosis-inducing effects of AD198 in human MM cells.
Conclusions: AD 198 and PEP005 have differential effects on malignant B cells through distinct biochemical
mechanisms. Our findings uncovered a novel, PKCδ-independent mechanism of the anti-tumor effects of AD 198,
and suggest that AD 198 has therapeutic potential for the treatment of NHL and MM involving TRAF3 inactivation
or c-Myc up-regulation.
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In the United States, lymphoid neoplasms are the 5th
most common human cancer with over 70,000 new
cases annually, resulting in approximately 21,000 deaths
per year [1-3]. For unknown reasons, the annual incidence
of non-Hodgkin lymphoma (NHL) has doubled since the
1970s [3]. Mature B cell neoplasms account for over 90%
of lymphoid tumors worldwide. Despite recent advances* Correspondence: xiep@rci.rutgers.edu
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reproduction in any medium, provided the orin treatment, many types of human B cell lymphomas
remain incurable, highlighting a clear need for new
preventative and therapeutic strategies [1-3]. Identification
and validation of novel genetic risk factors and critical
oncogenic pathways are imperative for further translational
efforts. In keeping with these goals, recent studies from
our laboratory and others have identified TRAF3, a critical
determinant of B cell survival [4,5], as a novel tumor
suppressor in a variety of human B cell lineage neoplasms.
Homozygous deletions and inactivating mutations of
the Traf3 gene have been identified in NHL, including
splenic marginal zone lymphoma (MZL), B cell chronicl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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oma (MCL), as well as multiple myeloma (MM) and
Waldenström’s macroglobulinemia (WM) [6-9].
TRAF3, a member of the TRAF family of cytoplasmic
adaptor proteins, has E3 ubiquitin ligase activity [10,11].
It was first identified as an interacting protein shared by
CD40 (a receptor pivotal for B cell activation) and LMP1
(an Epstein-Barr virus-encoded oncogenic protein) [12].
TRAF3 also binds to receptors for the critical B cell survival
factor BAFF, including BAFF-R, TACI and BCMA. Initial
studies of mice homozygous for a null allele of Traf3
showed that they died by day 10 after birth with severe
progressive runting and massive loss of splenic cellularity
[13]. To circumvent limitations imposed by this early
mortality and, more specifically, to explore the functions of
TRAF3 in B lymphocytes, we recently generated mice
bearing a conditional allele of TRAF3 [4]. By characterizing
mice that have the Traf3 gene specifically deleted in B
lymphocytes (B-TRAF3−/− mice), we found that TRAF3
deletion causes vastly prolonged survival of mature B cells
independent of BAFF, which eventually leads to B lymph-
oma development in mice [4,14]. Resting splenic B cells
from these mice show increased levels of active NF-κB2 but
decreased levels of nuclear PKCδ [4,5]. Using B lymphoma
cells derived from B-TRAF3−/− mice as model systems, we
demonstrated that oridonin, a pharmacological inhibitor of
NF-κB, and lentiviral vectors of NF-κB2 shRNAs induce
apoptosis in cultured TRAF3−/− B lymphoma cells [14].
These studies identified constitutive NF-κB2 activation as
one oncogenic pathway in TRAF3−/− B cells.
Interestingly, available evidence suggests that the second
signaling pathway downstream of TRAF3 inactivation, the
reduced PKCδ nuclear translocation, may also contribute
to prolonged B cell survival. First, the splenic B cell
compartment of PKCδ−/− mice is greatly expanded [15,16],
similar to that observed in B-TRAF3−/− mice [4,5] and
BAFF or NF-κB2 transgenic mice [17,18]. Second, the
physiological B cell survival factor, BAFF, also reduces
PKCδ nuclear levels in splenic B cells [19]. In light of these
observations, the present study sought to evaluate the
therapeutic potential of PKCδ activation in TRAF3−/−
tumor B cells using two pharmacological activators of
PKCδ, N-Benzyladriamycin-14-valerate (AD 198) and
ingenol-3-angelate (PEP005) [20-25]. We found that AD
198 exhibited potent in vitro and in vivo anti-tumor activity
on TRAF3−/− tumor B cells, while PEP005 displayed
contradictory anti- or pro-tumor activities on different cell
lines. Our detailed mechanistic investigation revealed that
AD 198 and PEP005 acted through distinct biochemical
mechanisms. Interestingly, although PKCδ was identified as
the principal target of AD 198 in other cancer cells,
AD 198-induced apoptosis of tumor B cells was mediated
through PKCδ-independent suppression of c-Myc expres-
sion. In contrast, PEP005 activated multiple signalingpathways in these cells, including PKCδ, PKCα, PKCε,
NF-κB1, ERK, JNK, and Akt. Furthermore, we extended
the investigation of AD 198 to TRAF3-sufficient malig-
nant B cells, and found that AD198 also potently inhibited
the proliferation/survival and suppressed c-Myc expres-
sion in TRAF3-sufficient mouse and human B lymphoma
cell lines. Taken together, our findings suggest that
AD 198 has therapeutic potential for the treatment of




TRAF3flox/floxCD19+/Cre (B-TRAF3−/−) and TRAF3flox/flox
(littermate control, LMC) mice were generated as previ-
ously described [4]. NOD SCID mice (Jackson Laboratory,
stock number: 001303, strain name: NOD.CB17-Prkdcscid/J)
were used as recipients in B lymphoma transplantation and
in vivo drug treatment experiments. All mice were kept in
specific pathogen-free conditions in the Animal Facility at
Rutgers University, and were used in accordance
with NIH guidelines and under an animal protocol
(Protocol # 08–048) approved by the Animal Care and
Use Committee of Rutgers University.
Cell lines and cell culture
Human MM cell lines 8226 (contains bi-allelic TRAF3
deletions), KMS11 (contains bi-allelic TRAF3 deletions) and
LP1 (contains inactivating TRAF3 frameshift mutations)
were generously provided by Dr. Leif Bergsagel (Mayo
Clinic, Scottsdale, AZ). Human B lymphoma cell lines
Daudi (Burkitt’s lymphoma), Ramos (Burkitt’s lymphoma),
and JeKo-1 (mantle cell lymphoma) were obtained from
American Type Culture Collection (ATCC, Manassas, VA).
All human MM and B lymphoma cell lines were cultured
as previously described [7]. Mouse B lymphoma cell lines
A20.2J and CH12.LX were generously provided by Dr. Gail
Bishop (University of Iowa, Iowa City, IA), and m12.4.1 was
purchased from ATCC. All mouse B lymphoma cell
lines were cultured as we described [14]. Generation
of TRAF3−/− mouse B lymphoma cell line 27–9.5.3
was described previously [14].
Mouse B lymphoma cell line 105–8.1B6 was generated
from ascites harvested from a B-TRAF3−/− mouse (mouse
ID: 105–8) [14]. Briefly, ascitic cells (5 × 105 cells/well) were
plated in 24-well plates in mouse B cell media [4] containing
10% fetal bovine serum. After being cultured for 2 months,
4 actively proliferating clones were expanded, passaged,
and frozen. The 105–8.1B6 clone had been cultured
for 5 months without obvious changes in morphology or
growth rate, and was used for drug treatment experiments.
Mouse B lymphoma cell line 115–6.1.2 was derived
from splenic B lymphoma of another B-TRAF3−/− mouse
(mouse ID: 115–6) [14]. Briefly, Primary splenic B
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serially passaged in NOD SCID mice twice. B lymphoma
cells (5 × 105 cells/well) harvested from transplanted
NOD SCID mice were plated in 24-well plates in mouse B
cell media containing 10% fetal bovine serum. After being
cultured for 1 month, 8 actively proliferating clones were
expanded, passaged, and frozen. The 115–6.1.2 clone had
been cultured for 5 months without obvious changes
in morphology or growth rate, and was used for drug
treatment experiments.Antibodies and reagents
Polyclonal rabbit Abs against RelB, NF-κB1, RelA, c-Rel,
HDAC1, and PKCδ were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Polyclonal rabbit Abs
specific for NF-κB2, c-Myc, phosphorylated PKCδ,
PKCα, PKCε, caspase 3, and COX IV, and Abs against
total or phosphorylated ERK, p38, JNK, and Akt, were from
Cell Signaling Technology (Beverly, MA). Anti-actin Ab
was from Chemicon (Temecula, CA). HRP-labeled second-
ary Abs were purchased from Jackson ImmunoResearch
Laboratories, Inc. (West Grove, PA). Tissue culture supple-
ments including stock solutions of sodium pyruvate,
L-glutamine, and non-essential amino acids and Hepes
(pH 7.55) were from Invitrogen (Carlsbad, CA). Oridonin
was purchased from CalBiochem (EMD Chemicals,
Gibbstown, NJ). AD 198, PEP005, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT), propidium
iodide (PI), hexadimethrine bromide (polybrene), and
rabbit anti-FLAG Abs were purchased from Sigma-
Aldrich Corp. (St. Louis, MO). Allophycocyanin (APC)-
conjugated-anti-Thy1.1 Ab was obtained from eBioscience
(San Diego, CA). TRIzol reagent was from Invitrogen, and
the High Capacity cDNA Reverse Transcription Kit was
purchased from Applied Biosystems (Carlsbad, CA). DNA
oligonucleotide primers were obtained from Integrated
DNA Technologies (Coralville, IA). Pfu UltraII was
purchased from Agilent (Santa Clara, CA).MTT assay
For primary TRAF3−/− B lymphomas, cells were cultured
for 4 days to obtain cleaner tumor cell populations for
MTT assays. Tumor cells (1 × 105 cells/well) were plated
in 96-well plates in the absence or presence of AD 198
or PEP005 of various concentrations. Twenty-four hours
later, total viable cell numbers were measured using the
MTT assay as described [14,26]. Possible influences
caused by direct MTT-drug interactions were excluded
by studies in a cell-free system. Wells with untreated
cells or with medium alone were used as positive and
negative controls, respectively. Total viable cell number
curves were plotted as a percentage of untreated control
cells [14,24,27].Measurement of apoptosis
Cell apoptosis was assessed by both cell cycle analyses of
the sub-G1 population and caspase 3 cleavage assays.
For cell cycle analyses, cells (3 × 105 cells/well) were cul-
tured in 24-well plates in the absence or presence of appro-
priate doses of AD 198 or PEP005 for 24 hours, and fixed
with ice-cold 70% ethanol. Cell cycle distribution was
determined by propidium iodide (PI) staining followed by
flow cytometry as previously described [4,28]. For caspase
3 cleavage assays, total cellular proteins were prepared
from cells at different time points after treatment with AD
198, and cleavage of caspase 3 was subsequently examined
by immunoblot analysis.
Lymphoma transplantation and drug treatment of NOD
SCID mice
TRAF3−/− mouse B lymphoma cell line 27–9.5.3 cells
(3 × 106 cells per mouse) were i.p. injected into NOD
SCID mice. On day 2 post transplantation, mice were
divided into 3 cohorts for administration with drugs
or with vehicle. Mice were i.p. injected with 150 μl
(for a 20 g mouse) of AD 198 (5 mg/kg), oridonin
(7.5 mg/kg), or vehicle (90% PBS and 10% DMSO).
Drug or vehicle injections were carried out three
times a week for 2 weeks. Transplanted NOD SCID
mice were monitored daily for tumor development, or
signs of illness or discomfort, including weight loss,
enlarged lymph nodes or abdomen, labored breathing,
hunched posture, and paralysis [29]. Histopathological
examination of diseased mice was performed as previ-
ously described [14,29].
Total protein lysates
Cells (for mouse B lymphoma, 10 × 106 cells per condition;
for human MM, 3.5 × 106 cells per condition) were treated
with appropriate doses of AD 198 or PEP005 for different
time periods. Cell pellets were lysed in 200 μl of 2X SDS
sample buffer (0.0625 M Tris, pH6.8, 1% SDS, 15% glycerol,
2% β-mercaptoethanol and 0.005% bromophenol blue),
sonicated for 30 pulses, and boiled for 10 minutes.
Cytosolic and nuclear extracts
Cells (for mouse B lymphoma, 10 × 106 per condition;
for human MM, 5 × 106 per condition) were treated
with appropriate doses of AD 198 or PEP005 for different
time periods. Cytosolic and nuclear extracts were pre-
pared from the cells as described [4,14]. Briefly, cells were
washed with ice-cold PBS, swelled in 500 μl of hypotonic
Buffer A (10 mM HEPES, pH7.5, 10 mM KCl, 0.1 mM
EDTA and 0.1 mM EGTA with protease and phosphatase
inhibitors) for 15 minutes, and then lysed by addition of
31.5 μl of 10% NP-40. Lysates were centrifuged at 13,000
rpm for 5 minutes, and the supernatants were harvested
as cytosolic extracts. The pellets were incubated with
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0.4 M NaCl, 1 mM EDTA and 1 mM EGTA with
protease and phosphatase inhibitors), vigorously agitated at
4°C for 45 minutes, and centrifuged at 13,000 rpm for 10
minutes at 4°C. The resulting supernatants in Buffer C were
harvested as nuclear extracts. One-fifth volume of 5× SDS
sample buffer was added into each cytosolic or nuclear
extracts, which were subsequently boiled for 10 minutes.
Fractionation of cytosol, nuclei and membranes
Cells (for mouse B lymphoma, 30 × 106 cells per condition;
for human MM, 15 × 106 cells per condition) were treated
with appropriate doses of AD 198 or PEP005 for 5, 10 or
30 minutes. Cytosol, nuclei and membranes were fraction-
ated from cells as previously described [23,24]. Briefly, cells
were washed with ice-cold PBS, swelled in 700 μl of hypo-
tonic Buffer M (10 mM HEPES, pH7.5, 10 mM KCl, 1 mM
EDTA, 0.1 mM EGTA and 250 mM sucrose with protease
and phosphatase inhibitors) on ice for 10 minutes, and
then homogenized in a Dounce homogenizer. Cell lysis
was checked by trypan blue uptake. Nuclei were isolated
by centrifugation at 2,000 rpm for 10 minutes at 4°C. The
supernatants were transferred to new tubes, and centrifu-
gation at 13,000 rpm for 45 minutes was used to separate
cytosol (supernatant) from membrane (pellet) fractions.
One-fifth volume of 5× SDS sample buffer was added into
the cytosol fraction. The pellets of nuclei and membranes
were lysed in 200 μl of 2× SDS sample buffer respectively,
and sonicated for 10 pulses. All protein samples were
subsequently boiled for 10 minutes.
Immunoblot analysis
Aliquots of total protein lysates, cytosolic and nuclear
extracts, or fractions of cytosol, nuclei and membranes
were separated by SDS-PAGE, and electroblotted onto
nitrocellulose membranes (ProTran, Schleicher & Schuell
BioScience, Keene, NH). Immunoblot analysis was per-
formed using various antibodies as previously described
[30]. Images of immunoblots were acquired using a
low-light imaging system (LAS-4000 mini, FUJIFILM
Medical Systems USA, Inc., Stamford, CT).
Taqman assay of c-Myc mRNA expression
Cells (for mouse B lymphoma, 10 × 106 cells per condition;
for human MM, 5 × 106 cells per condition) were treated
with appropriate doses of AD 198 for different time
periods. Total cellular RNA was extracted using TRIzol
reagent (Invitrogen) according to the manufacturer’s proto-
col. Complementary DNA (cDNA) was prepared from
RNA using High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). Quantitative real-time PCR was
performed using TaqMan Gene Assay kit (Applied
Biosystems). TaqMan primers and probes (FAM-labeled)
specific for mouse or human c-Myc were used in the PCRreaction to detect c-Myc mRNA in mouse B lymphoma and
human MM cells, respectively. Each reaction also included
primers and the probe (VIC-labeled) specific for mouse or
human β-actin mRNA, which served as endogenous
control. Relative mRNA expression levels of c-Myc
were analyzed using the Sequence Detection Software
(Applied Biosystems) and the comparative Ct (ΔΔCt)
method following the manufacturer’s procedures. For each
biological sample, duplicate PCR reactions were performed.
Generation of lentiviral c-Myc expression vectors
The c-Myc coding cDNA sequence was cloned from the
human MM cell line 8226 cells by reverse transcription
and high-fidelity PCR using primers human c-Myc-F
(5′- ACG ATG CCC CTC AAC GTTAG -3′) and human
c-Myc-R (5′- TCC TTA CGC ACA AGA GTT CC -3′).
The high-fidelity polymerase Pfu UltraII (Agilent) was
used in the PCR reaction. The c-Myc coding cDNA
sequence was subcloned into the lentiviral expression vec-
tor pUB-eGFP-Thy1.1 [31] (kindly provided by Dr. Zhibin
Chen, the University of Miami, Miami, FL) by replacing
the eGFP coding sequence with the c-Myc coding
sequence. To facilitate the differentiation of trans-
duced c-Myc from endogenous c-Myc, we engineered
an N-terminal FLAG tag in frame with the c-Myc
coding sequence, and generated a lentiviral expression vec-
tor of FLAG-tagged c-Myc (pUB-FLAG-c-Myc-Thy1.1).
The human c-Myc coding sequence and the lentiviral
expression vectors were verified by DNA sequencing.
Lentiviral packaging and transduction of human MM cells
Lentiviruses of the pUB-FLAG-c-Myc-Thy1.1 vector or
an empty lentirival vector pUB-Thy1.1 were packaged
and titered as previously described [31,32]. The pUB
lentiviral expression vectors have an expression cassette
of the marker Thy1.1, and thus allow the transduced
cells to be analyzed by Thy1.1 immunofluorescence
staining followed by flow cytometry. Human MM cell
lines 8226 and LP1 cells were transduced with the packaged
lentiviruses at a multiplicity of infection (MOI) of 1:5
(cell:virus) in the presence of 8 μg/ml polybrene [31].
On day 4 post transduction, the transduction efficiency of
cells was analyzed by flow cytometry. Transduced cells
were subsequently analyzed for c-Myc protein expression
and responses to treatment with AD 198.
Statistics
Statistical analyses were performed using the Prism soft-
ware (GraphPad, La Jolla, CA). Survival curves were gener-
ated using the Kaplan-Meier method, and were compared
using a log-rank (Mantel-Cox) test to determine whether
differences are significant. For other experiments, statistical
significance was assessed by Student t test. P values less
than 0.05 are considered significant.
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Differential effects of AD 198 and PEP005 on
TRAF3-/- tumor B cells
We recently reported that decreased PKCδ nuclear trans-
location is a feature of both premalignant TRAF3−/− B cells
and primary TRAF3−/− B lymphomas derived from
B-TRAF3−/− mice [4,14]. It has also been shown that
PKCδ−/− mice have greatly increased numbers of B
cells and that inhibition of PKCδ nuclear translocation
contributes to BAFF-mediated survival of peripheral B cells
[15,16,19]. These previous studies suggest that PKCδ
nuclear translocation is a downstream signaling event of
TRAF3 and induces apoptosis in B cells. This
prompted us to test the possibility that restoration of
PKCδ nuclear translocation may have therapeutic potential
in TRAF3−/− tumor B cells. We thus evaluated the effects
of two pharmacological activators of PKCδ, AD 198 and
PEP005, on primary TRAF3−/− B lymphomas harvested
from diseased B-TRAF3−/− mice. Our results of MTT
assays demonstrated that AD 198 exhibited potent
anti-proliferative/survival-inhibitory effects on primary
TRAF3−/− B lymphoma cells in a dose-dependent
manner (effective doses: 0.1 to 1 μM) (Figure 1A and 1B).
In sharp contrast, PEP005 stimulated the proliferation of
primary TRAF3−/− B lymphoma cells at the dose range
(10 to 100 nM) that has been previously shown to display
anti-tumor activity on myeloid leukemia cells [23,24]
(Additional file 1: Figure S1A and 1B).
We then compared the effects of AD 198 and PEP005
on three TRAF3−/− B lymphoma cell lines derived
from different individual B-TRAF3−/− mice, including
105–8.1B6, 115–6.1.2 and 27–9.5.3 [14]. These 3 cell
lines differ in their Ig VDJ sequences, malignant
states, and metastatic capabilities. The 105–8.1B6 cell
line is IgM+, does not contain somatic hypermutation
(SHM) in the Ig VDJ region, and develops peritoneal
and splenic B lymphomas within 4 months when
transplanted into NOD SCID recipient mice. The
115–6.1.2 cell line is IgM+, contains SHM in the Ig
VDJ region, and develops peritoneal and splenic B
lymphomas within 2 months when transplanted into
NOD SCID recipient mice, which occasionally metas-
tasize to the kidney and liver. The 27–9.5.3 cell line
is IgG+, contains SHM in the Ig VDJ region, and
develops peritoneal and splenic B lymphomas, which
often metastasize to the kidney, liver and lung within
3 weeks when transplanted into NOD SCID recipient
mice. We found that AD 198 consistently exhibited
potent anti-proliferative/survival-inhibitory effects on all 3
TRAF3−/− B lymphoma cell lines in a dose-dependent
manner (effective doses: 0.25 to 4 μM) (Figure 1C). In
contrast, PEP005 displayed contradictory effects on
these 3 cell lines. PEP005 induced the proliferation of
105–8.1B6 cells, killed 115–6.1.2 cells, and did notaffect 27–9.5.3 cells at the dose range of 12.5 to 100 nM
(Additional file 1: Figure S1C).
To extend the clinical relevance of our findings, we
further examined the effects of AD 198 and PEP005 on
three human patient-derived MM cell lines with TRAF3
deletions or mutations: 8226, KMS11 and LP1. Both
8226 and KMS11 cell lines contain bi-allelic deletions of
the Traf3 gene, while LP1 cell line has frameshift muta-
tions of Traf3 [14]. These cell lines represent naturally
occurring TRAF3−/− tumor B cells. Our results of MTT
assays showed that the responses of the 3 human MM
cell lines to AD 198 and PEP005 recapitulated those of
mouse TRAF3−/− B lymphoma cell lines (Figure 1D and
Additional file 1: Figure S1D). Together, these data indi-
cate that AD 198 exhibits potent anti-proliferative/-
survival-inhibitory effects, whereas PEP005 displays
divergent effects on TRAF3−/− mouse B lymphoma cells
and human MM cells.
AD 198 but not PEP005 induced apoptosis in
TRAF3-/- tumor B cells
To understand the mechanism of AD 198 and PEP005,
we first performed cell cycle analysis using PI staining
followed by flow cytometry. We found that AD 198
induced TRAF3−/− mouse B lymphoma cells and human
MM cells to undergo apoptosis, as demonstrated by the
drastic increase of the sub-G1 population with DNA
content < 2n (Figure 2A and 2B). AD 198 also inhibited
the proliferation of TRAF3−/− tumor B cells, as shown
by the marked decrease of the population at the S/G2/M
phase (2n < DNA content ≤ 4n) (Figure 2A and 2B). In
contrast, PEP005 increased the population at the S/G2/M
phase in mouse 105–8.1B6 and human 8226 cells, but
induced the apoptotic population and decreased the
population at the S/G2/M phase in mouse 115–6.1.2 cells.
PEP005 did not have significant effects on the cell cycle
distribution in mouse 27–9.5.3 as well as human KMS11
and LP1 cell lines (Additional file 1: Figure S2A and 2B).
We next determined whether AD 198 induced the activa-
tion of the key effector caspase, caspase 3, involved in
apoptosis. We found that AD 198 induced the rapid acti-
vation of caspase 3, as evidenced by the cleavage of
caspase 3 as early as three hours after treatment with AD
198 in TRAF3−/− mouse B lymphoma and human MM
cell lines (Figure 2C). Collectively, our data demonstrate
that AD 198 but not PEP005 induces rapid apoptosis in
TRAF3−/− tumor B cells.
AD 198 exhibited potent in vivo anti-tumor activity on
TRAF3−/− mouse B lymphomas
The potent in vitro anti-proliferative/apoptosis-inducing
effects of AD 198 led us to further assess its in vivo
therapeutic potential. We recently reported that B-TRAF3−/−
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Figure 1 AD 198 exhibited potent anti-proliferative/survival-inhibitory effects on TRAF3-/- mouse B lymphoma and human MM cells.
Tumor B cells were treated with various concentrations of AD 198 for 24 h. Total viable cell numbers were subsequently determined by MTT
assay. (A and B) Effects on primary splenic B lymphoma cells harvested from diseased B-TRAF3−/− mice. Panel A shows the activity of AD 198
examined with a wide range of doses (1:10 serial dilutions). Panel B shows refined dose-dependent effects of AD 198 (examined at 1:2 serial
dilutions). Similar results were also obtained with primary B lymphoma cells purified from ascites, cervical and mesenteric LNs of several individual
B-TRAF3−/− mice with spontaneous tumors. (C) Effects on TRAF3−/− B lymphoma cell lines derived from 3 individual B-TRAF3−/− mice, including
105–8.1B6 (105–8), 115–6.1.2 (115–6), and 27–9.5.3 (27–9). (D) Effects on human patient-derived MM cell lines with TRAF3 bi-allelic deletions or
frameshift mutations, including 8226, KMS11 and LP1. The graphs depict the results of three independent experiments with duplicate samples in
each experiment (mean ± SEM).
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are not ideal for drug treatment experiments. In this study,
we used NOD SCID mice transplanted with the highly
malignant TRAF3−/− B lymphoma cell line 27–9.5.3 as
model systems for in vivo drug treatment experiments. We
also included the study of oridonin, an inhibitor of NF-κB2
and NF-κB1 activation, which also exhibits robust in vitro
tumoricidal activity on primary TRAF3−/− B lymphomas
harvested from diseased B-TRAF3−/− mice [14].
In the absence of drug treatment, transplantation of
27–9.5.3 cells (3 × 106 cells/mouse) caused rapid B lymph-
oma development in NOD SCID mice, which killed the
mice at 23 ± 3 (Mean ± SD) days post-transplantation
(Figure 3). Necropsy revealed that B lymphomas were notonly developed in the peritoneal cavity and spleen, but
also often metastasized to the kidney, liver and lung.
Treatment of transplanted NOD SCID mice with oridonin
significantly prolonged the survival of mice to 30 ± 3.7
days post-transplantation (p = 0.0043, determined by the
Mantel-Cox log-rank test). However, metastasis to the
kidney, liver and lung was also common in oridonin-
treated mice. Interestingly, administration of AD 198 into
transplanted NOD SCID mice vastly extended the survival
of mice to 46 ± 12 days post-transplantation (p < 0.0001,
determined by the Mantel-Cox log-rank test). Further-
more, B lymphomas were typically localized in the peri-
toneal cavity, and metastasis to the kidney, liver and lung
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Figure 2 (See legend on next page.)
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Figure 2 AD 198 induced apoptosis in TRAF3−/− tumor B cells. (A and B) Cell cycle distribution determined by PI staining and flow
cytometry. TRAF3−/− mouse B lymphoma cell lines (A) or human MM cell lines (B) were cultured in the absence or presence of AD 198 of
indicated concentration for 24 h, and then fixed. Fixed cells were stained with PI and analyzed by FACS. Representative histograms of PI staining
are shown, and percentage of apoptotic cells (DNA content < 2n; sub-G1) and proliferating cells (2n < DNA content ≤ 4n; S/G2/M) are indicated.
Results are representative of 3 independent experiments. (C) Western blot analysis of caspase 3 cleavage. Cells were cultured in the absence or
presence of AD 198 of indicated concentration. Total cellular lysates were prepared at indicated time points, and then immunoblotted for
caspase 3, followed by actin. Immunoblots of actin were used as loading control. Results are representative of three independent experiments.
Similar results were also obtained with other cell lines examined.
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serve any adverse effects of AD 198 at the dose examined
(5 mg/kg) in mice, such as weight loss or liver damage.
Taken together, our results demonstrate that both AD 198
and oridonin exhibit in vivo anti-tumor activity on
TRAF3-/- mouse B lymphomas.
AD 198 induced PKCδ cleavage, while PEP005 induced
PKC translocation in TRAF3-/- tumor B cells
Both AD 198 and PEP005 have been previously shown
to induce the subcellular translocation of PKCδ in
myeloid leukemia cells, which mediates the anti-leukemic
effects of these two drugs [20,21,23,24]. PKCδ nuclear
translocation also regulates B cell apoptosis [15,16,19].
We thus compared the effects of AD 198 and PEP005 on
PKCδ nuclear translocation using cytosolic and nuclear
extracts, which were prepared by the same method
described in our previous studies [4,14]. Surprisingly,
neither AD 198 nor PEP005 increased the nuclear levels




















Oridonin vs CTL: P = 0.0043
n = 6n = 12
AD 198 vs CTL: P < 0.0001
n = 8
Figure 3 AD 198 and oridonin exhibited potent anti-tumor
activity on transplanted TRAF3−/− B lymphomas in NOD SCID
mice. TRAF3−/− mouse B lymphoma cell line 27–9.5.3 cells
(3 x 106 per mouse) were i.p. injected into NOD SCID recipient mice.
On day 2 post transplantation, mice were divided into 3 cohorts for
administration with drugs or with vehicle. Mice were i.p. injected
with 150 μl (for a 20 g mouse) of AD 198 (5 mg/kg, n = 8), oridonin
(7.5 mg/kg, n = 6), or vehicle (90% PBS and 10% DMSO; CTL,
n = 12). Drug or vehicle injections were carried out three times a
week for 2 weeks. Transplanted NOD SCID mice were monitored
daily for tumor development as described in the Methods. Survival
curves of mice were generated using the Kaplan-Meier method. P
value of AD 198 vs. CTL is <0.0001, and P value of oridonin vs. CTL is
0.0043, as determined by the Mantel-Cox log-rank test.cells (Figure 4A and Additional file 1: Figure S3A).
Interestingly, we noticed that AD 198 but not PEP005
induced the cleavage of cytosolic PKCδ from the 78
kDa holoenzyme to the 40 kDa catalytic fragment at
6 hours after treatment in a dose dependent manner
(Figure 4A and Additional file 1: Figure S3A). We
next determined the time-course effects of AD 198
and PEP005 on PKCδ nuclear translocation or cleavage.
We found that neither AD 198 nor PEP005 increased the
nuclear levels or cleavage of PKCδ at 5 to 60 minutes after
treatment (Figure 4B and Additional file 1: Figure S3B). In
these experiments, we also examined the effects of AD
198 and PEP005 on the other oncogenic pathways that we
recently identified, NF-κB2 and NF-κB1 activation [14]. It
has been shown that AD 198 and PEP005 promote
NF-κB1 activation in breast cancer and primary acute
myeloid leukemia cells [22,37,38]. No obvious effects
of AD 198 were observed on nuclear levels of NF-κB2
(p52/p100) or NF-κB1 subunits (p50, c-Rel and RelA),
except for a moderate inhibition of RelB levels by the
highest dose of AD 198 examined (Figure 4A). The only
noticeable effect of PEP005 was the increase of nuclear
RelA and c-Rel levels at 15 to 60 minutes after treatment
in mouse 105–8 cells (Additional file 1: Figure S3B).
Our unexpected results of PKCδ nuclear translocation
prompted us to compare our biochemical method of
nuclear extraction with the previous method used to
study AD 198 and PEP005 in myeloid leukemia cells.
We identified one major difference in the methods: our
nuclear extracts did not include proteins localized at or
associated with the nuclear membrane, but the nuclei
fraction prepared in previous studies of AD 198 and
PEP005 did. We thus prepared subcellular fractions of
cytosol, nuclei, and membrane (including mitochondria)
using the method that was previously employed in the
study of AD 198 and PEP005 in myeloid leukemia cells
[23,24]. As shown in Figure 5A, our results clearly demon-
strated that PEP005 induced the rapid translocation of
PKCδ, PKCε and PKCα from the cytosol to the nuclei
and membranes (including mitochondria) in TRAF3−/−
mouse B lymphoma cells. Similarly, PEP005 induced the
rapid translocation of PKCα from the cytosol to the
nuclei and membranes in TRAF3−/− human MM cells
(Figure 5A). However, in sharp contrast, AD 198 did
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Figure 4 (See legend on next page.)
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Figure 4 AD 198 did not affect PKCδ nuclear translocation or NF-κB activation. (A) Dose-dependent effects of AD 198. Mouse or human
tumor B cells were cultured in the absence or presence of various concentrations of AD 198 for 6 h. (B) Time-dependent effects of AD 198.
Mouse or human tumor B cells were cultured in the absence or presence of AD 198 (1 μM for 105–8 cells and 2 μM for 8226 cells) for indicated
time periods. Cytosolic and nuclear extracts were prepared as described in the Methods. Proteins were immunoblotted for PKCδ, NF-κB2
(p100 – p52), RelB, NF-κB1 (p50), c-Rel, and RelA, followed by HDAC1 and actin. Immunoblots of actin and HDAC1 were used as loading control
for cytosolic and nuclear proteins, respectively. Results are representative of three independent experiments. Similar results were also obtained
with other cell lines examined.
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or PKCα in any TRAF3−/− tumor B cell lines examined in
this study (Figure 5A).
It is known that activation of PKCδ is not only regulated
by subcellular translocation, but also modulated by phos-
phorylation and cleavage of PKCδ [39,40]. Subcellular
translocation allows PKCδ to access its nuclear substrates
(such as DNA damage response proteins DNA-dependent
protein kinase, Rad9 and p53) and mitochondrial substrates
(such as an anti-apoptotic protein Mcl-1 and a regulator
of phospholipid movement Phospholipid Scramblase 3)
[39,40]. Cleavage of PKCδ removes the N-terminal auto-
inhibitory regulatory domain from the catalytic fragment
of PKCδ, thereby causing activation of PKCδ in the
absence of any co-factors [39,40]. Depending on the
stimuli and the cellular context, phosphorylation of
PKCδ may regulate its subcellular translocation, cleavage,
or substrate selectivity [39,40]. In light of these previous
findings, we further assessed the effects of AD 198 on the
phosphorylation and cleavage of PKCδ in TRAF3−/− tumor
B cell lines. We found that AD 198 did not induce the
phosphorylation of PKCδ from 10 minutes up to 6 hours
after treatment in any TRAF3−/− tumor B cell lines exam-
ined in this study (Figure 5A and 5B). Interestingly, AD 198
did induce the cleavage of PKCδ at 6 hours after treatment
in TRAF3−/− tumor B cells (Figures 4A and 5B). However,
the induction of PKCδ cleavage occurred relatively late, and
was preceded by caspase 3 activation, which was detected
at 3 hours after AD 198 treatment (Figure 2C). It has been
previously shown that PKCδ is a substrate of caspase 3,
which cleaves the 78 kDa holoenzyme of PKCδ to generate
the 40 kDa catalytic fragment of PKCδ [41]. Therefore, it is
very likely that PKCδ cleavage induced by AD 198 is a
consequence of caspase 3 activation in TRAF3−/− tumor B
cells, and is not the initiating signal that triggers the apop-
tosis. Taken together, our findings suggest that AD 198
induces the apoptosis of TRAF3−/− tumor B cells not
through the translocation or activation of its known target
PKCδ, but through a distinct novel mechanism.
Differential effects of AD 198 and PEP005 on ERK, p38
and JNK activation in TRAF3−/− tumor B cells
To gain further insights into the molecular mechanisms
underlying the anti-tumor effect of AD 198 and thedivergent effects of PEP005, we next sought to investigate
key signaling pathways that are known to play important
roles in regulating B cell survival and proliferation, including
the activation of ERK, p38, JNK, and Akt. We found that
AD 198 markedly and rapidly decreased the phos-
phorylation levels of ERK1 (p44), ERK2 (p42), and
p38 in TRAF3−/− mouse B lymphoma and human
MM cells (Figure 6A and 6B). Inhibition of ERK and
p38 phosphorylation was detected as early as 5 minutes
after AD 198 treatment. AD 198 also inhibited JNK activa-
tion in TRAF3−/− human MM cells. Interestingly, although
Akt activation is considered as a general survival pathway,
AD 198 increased the Ser473 phosphorylation and thus
activation of Akt in TRAF3−/− mouse B lymphoma and
human MM cells. In contrast, PEP005 induced the activa-
tion of ERK, JNK and Akt in TRAF3−/− mouse B lymph-
oma cells, and also induced ERK and Akt activation in
human MM cells (Figure 6A). Taken together, our results
suggest that the differential effects of AD 198 and PEP005
on tumor B cells are mediated by their distinct effects on
multiple signaling pathways, including PKCδ, PKCε, and
PKCα translocation (Figure 5A), and ERK, p38 and JNK
phosphorylation (Figure 6A).
AD 198 rapidly suppressed c-Myc expression in
TRAF3−/− tumor B cells
One known target gene of ERK, p38 and JNK signaling
pathways that is especially essential for B cell survival and
proliferation is c-Myc [42-44]. In light of our evidence that
AD 198 inhibited ERK, p38 and JNK signaling pathways,
we further investigated the effects of AD 198 on c-Myc
protein levels. We found that AD 198 potently decreased
protein levels of c-Myc, which was primarily localized in
the nucleus, in a dose-dependent manner at 6 hours after
treatment in TRAF3−/− mouse B lymphoma and human
MM cells (Figure 7A). We next found that AD 198 vastly
inhibited c-Myc protein levels as early as 1 hour after
treatment in all TRAF3−/− tumor B cell lines examined in
this study (Figure 7B). In contrast, PEP005 did not inhibit
c-Myc protein levels in any tumor B cell lines examined
(Additional file 1: Figure S3).
To understand the mechanism of AD198-mediated sup-
pression of c-Myc protein levels, we examined the mRNA















































1 M AD 198
10’ 30’ 60’0 3h 6h
Human (8226)
4 M AD 198






















































Figure 5 Differential effects of AD 198 and PEP005 on PKCδ subcellular translocation and cleavage. (A) Subcellular translocation of PKC
isoforms. Mouse or human tumor B cells were cultured in the absence or presence of AD 198 or PEP005 for 10 minutes. Drug concentrations
used: 1 μM AD 198 and 0.1 μM PEP005 for 105–8 cells; 4 μM AD 198 and 0.2 μM PEP005 for 8226 cells. Biochemical fractionation of cytosol,
nuclei and membrane was performed as described in the Methods. Proteins were immunoblotted for PKCδ, phosphorylated-PKCδ (P-PKCδ), PKCε,
and PKCα, followed by COXIV, HDAC1, and actin. Immunoblots of actin, HDAC1, and COX IV were used as loading control for proteins of cytosol,
nuclei, or membrane (including mitochondria), respectively. Similar results were also obtained at 5 minutes or 30 minutes after treatment, and
with another TRAF3−/− mouse B lymphoma cell line 27–9.5.3 and another human MM cell line 8226 (except barely detectable levels of PKCα in
8226 cells). (B) Phosphorylation and cleavage of PKCδ. Cells were cultured in the absence or presence of AD 198 of indicated concentration. Total
cellular lysates were prepared at indicated time points, and then immunoblotted for phosphorylated-PKCδ (P-PKCδ), PKCδ, followed by actin.
Similar results were also obtained with other cell lines examined. Results are representative of three independent experiments.
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Figure 6 AD 198 inhibited the phosphorylation of ERK, p38 and JNK in TRAF3−/− tumor B cells. (A) Phosphorylation of MAPK and Akt analyzed
by immunoblot analysis. Mouse or human tumor B cells were cultured in the absence or presence of AD 198 or PEP005 for indicated time periods. Drug
concentrations used: 1 μM AD 198 and 0.1 μM PEP005 for 105–8 cells; 4 μM AD 198 and 0.2 μM PEP005 for 8226 cells. Total cellular lysates were
prepared, and then immunoblotted for phosphorylated (P-) or total ERK, p38, JNK, and Akt, followed by actin. (B) Quantitation of ERK and p38
phosphorylation. Phosphorylated and total ERK1, ERK2, and p38 bands on immunoblots were quantitated using a low-light imaging system, and the
results are presented graphically. The amount of P-ERK1, P-ERK2, or P-p38 in each lane was normalized to the intensity of the corresponding total ERK1,
ERK2 or p38 band. The graphs depict ERK and p38 phosphorylation observed in three independent experiments (mean ± SD).
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Figure 7 (See legend on next page.)
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Figure 7 AD 198 suppressed c-Myc expression in TRAF3−/− tumor B cells. (A) Dose-dependent effects of AD 198 on c-Myc protein levels.
Mouse or human tumor B cells were cultured in the absence or presence of various concentrations of AD 198 for 6 h. Cytosolic and nuclear
extracts were prepared as described in the Methods. (B) Time-dependent effects of AD 198 on c-Myc protein levels. Mouse or human tumor B
cells were cultured in the absence or presence of AD 198 (1 μM for 105–8 cells and 4 μM for 8226 cells). Total cellular lysates were prepared at
indicated time points. Proteins were immunoblotted for c-Myc, followed by actin. Immunoblots of actin were used as loading control. Results of
A and B are representative of three independent experiments. Similar results were also obtained with other TRAF3−/− cell lines. (C) c-Myc
transcript levels analyzed by real time PCR. Cells were treated with AD 198 for indicated time periods. Drug concentrations used: 1 μM AD 198 for
105–8 cells; 2 μM AD 198 for 27–9 cells; 4 μM AD 198 for 8226 and KMS11 cells. Total cellular RNA was extracted and reverse transcribed.
Quantitative real-time PCR was performed using TaqMan primers and probe (FAM-labeled) specific for c-Myc. Each PCR reaction also included
primers and the probe (VIC-labeled) specific for β-actin mRNA, which served as endogenous control. Relative mRNA expression levels of c-Myc
were analyzed using the Sequence Detection Software and the comparative Ct (ΔΔCt) method. Graphs depict the results of three independent
experiments with duplicate samples in each experiment (mean ± SEM).
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http://www.biomedcentral.com/1471-2407/13/481real time PCR analyses. As shown in Figure 7C, AD 198
dramatically and rapidly inhibited the mRNA levels of
c-Myc in TRAF3−/− mouse B lymphoma and human MM
cells. Decrease in c-Myc mRNA levels was detected as
early as 10 minutes after AD 198 treatment, and could
completely account for the decrease in c-Myc protein
levels observed in these cells. These results indicate that
AD 198 potently suppresses c-Myc mRNA and protein
expression in TRAF3−/− tumor B cells.AD 198 exhibited potent anti-tumor activity and rapidly
suppressed c-Myc expression in TRAF3-sufficient B
lymphoma cell lines
Considering that elevated expression of c-Myc is associated
with many B cell malignancies [45], we further tested the
therapeutic effects of AD 198 on TRAF3-sufficient B
lymphoma cell lines. These include mouse B lymphoma
cell lines A20.2J, m12.4.1, and CH12.LX, and human B
lymphoma cell lines Daudi (Burkitt’s lymphoma), Ramos
(Burkitt’s lymphoma), and JeKo-1 (mantle cell lymphoma).
Our results of MTT assays demonstrated that AD 198 also
exhibited potent anti-proliferative/apoptosis-inducing
effects (effective dose: 0.25 to 4 μM) on all the TRAF3-
sufficient mouse and human B lymphoma cell lines exam-
ined in this study (Figure 8A). To determine whether c-Myc
is also the principal target of AD 198 in TRAF3-sufficient B
lymphoma cells, we examined the effects of AD 198 on
c-Myc protein levels. We found that AD 198 strikingly
inhibited c-Myc protein levels as early as 1 hour after
treatment in all TRAF3-sufficient B lymphoma cell
lines examined in this study (Figure 8B). AD 198 also
induced the cleavage and activation of caspase 3 at 3
hours after treatment in these cell lines. It should be
noted that c-Myc suppression precedes caspase 3 acti-
vation, suggesting that c-Myc is not the consequence,
but may be the trigger of apoptosis. Together, these
results indicate that AD 198 also has therapeutic
potential and targets c-Myc in TRAF3-sufficient B
lymphomas.Lentiviral vector-mediated constitutive expression of
c-Myc conferred partial resistance to the anti-tumor effects
of AD 198 in human MM cell lines
To further investigate whether c-Myc suppression
contributes to the anti-tumor effects of AD 198 in
malignant B cells, we performed reconstitution of c-Myc
expression experiments. We generated a lentiviral expres-
sion vector of FLAG-tagged human c-Myc, pUB-FLAG-c-
Myc-Thy1.1, in which constitutive expression of c-Myc is
driven by the ubiquitin promoter. Human MM cell lines
8226 and LP1 cells were transduced with this vector or an
empty lentiviral expression vector (pUB-Thy1.1), and then
analyzed for their responses to AD 198 treatment. Trans-
duction efficiency of the lentiviral vectors was over 90% in
human MM cells, as demonstrated by immunofluorescence
staining and flow cytometry (Figure 9A). Following
treatment with AD 198, although endogenous c-Myc
protein levels were strikingly decreased, the transduced
FLAG-c-Myc protein levels were not suppressed by AD
198 as shown in the immunoblots of both FLAG and
c-Myc (Figure 9B). These results demonstrated that
expression of the transduced FLAG-c-Myc driven by
the ubiquitin promoter was not suppressed by AD
198, suggesting that AD 198 inhibits the transcription
of endogenous c-Myc via its effects on the c-Myc promoter.
Interestingly, we further found that constitutive expression
of FLAG-c-Myc substantially counteracted the effects of
AD 198 on the proliferation and survival of human MM
cells (Figure 9C). Thus, our results indicate that c-Myc
suppression is a major contributing factor to the anti-tumor
effects of AD 198 in human MM cells.Discussion
We previously showed that premalignant TRAF3−/− B cells
and TRAF3−/− B lymphomas have decreased nuclear levels
of PKCδ [4,14]. This, together with the evidence that
decreased nuclear translocation of PKCδ promotes B cell
survival [15,16,19], prompted us to evaluate the therapeutic
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Figure 8 AD 198 exhibited potent anti-tumor activity and suppressed c-Myc expression in TRAF3-sufficient mouse and human B
lymphoma cell lines. (A) Anti-tumor activity of AD 198. Mouse B lymphoma cell lines A20.2 J, m12.4.1 and CH12.LX, or human B lymphoma cell
lines Daudi, Ramos and JeKo-1 were treated with various concentrations of AD 198 for 24 h. Total viable cell numbers were subsequently
determined by MTT assay. The graphs depict the results of three independent experiments with duplicate samples in each experiment
(mean ± SEM). (B) Time-dependent effects of AD 198 on c-Myc protein levels. Mouse or human B lymphoma cells were cultured in the absence
or presence of AD 198 of indicated concentrations. Total cellular lysates were prepared at indicated time points. Proteins were immunoblotted for
c-Myc, followed by caspase 3 and actin. Immunoblots of actin were used as loading control. Results are representative of three
independent experiments.
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the present study, we report that AD 198 exhibited potent
in vitro and in vivo anti-tumor activity on TRAF3−/− tumor
B cells, while PEP005 displayed contradictory anti- or
pro-tumor activities on different cell lines. AD 198
and PEP005 induced differential effects on TRAF3−/− tumor
B cells through distinct biochemical mechanisms. Our
detailed mechanistic study uncovered a novel PKCδ-
independent mechanism of the anti-tumor effect of
AD 198 that involves c-Myc suppression. Furthermore, we
found that AD 198 also exhibited potent anti-tumoreffects and targeted c-Myc in TRAF3-sufficient mouse
and human B lymphoma cell lines. Our findings suggest
that AD 198 has therapeutic potential for the treatment of
NHL and MM involving TRAF3 inactivation or c-Myc
up-regulation.
Ingenol-3-angelate (PEP005) is an active ingredient of
the sap from Euphorbia peplus, which has been used for
centuries in the U.K. and Australia as a traditional treatment
for skin conditions, including warts, corns and skin cancers.
PEP005 has now entered phase II clinical trials as a topical







































Figure 9 Constitutive c-Myc expression counteracted the effects of AD 198 on the proliferation and survival of human MM cells. The
human MM cell line 8226 cells were transduced with a lentiviral expression vector of FLAG tagged c-Myc (pUB-FLAG-c-Myc-Thy1.1, labeled as
pUB-FLAG-Myc in the figure). Cells transduced with an empty lentiviral expression vector (pUB-Thy1.1) were used as control in these experiments.
(A) Transduction efficiency analyzed by Thy1.1 immunofluorescence staining and flow cytometry. Gated population (Thy1.1+) indicates cells
successfully transduced with each lentiviral expression vector. Untransduced 8226 cells were used as negative control. (B) Time-dependent effects
of AD 198 on endogenous c-Myc and transduced FLAG-c-Myc protein levels. Transduced 8226 cells (8226/pUB-Thy1.1 or 8226/pUB-FLAG-Myc)
were cultured in the absence or presence of 4 μM AD 198. Total cellular lysates were prepared at indicated time points, and were
immunoblotted for FLAG, c-Myc, followed by actin. Immunoblots of actin were used as loading control. Results are representative of three
independent experiments. (C) Decreased anti-proliferative/survival-inhibitory effects of AD 198 on human MM cells with constitutive c-Myc
expression. Transduced 8226 cells (8226/pUB-Thy1.1 or 8226/pUB-FLAG-Myc) were treated with various concentrations of AD 198 for 24 h. Total
viable cell numbers were subsequently determined by MTT assay. The graph depicts the results of three independent experiments with duplicate
samples in each experiment (mean ± SEM). Similar results were also observed in another human MM cell line LP1 cells.
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treatment for acute myeloid leukemia in preclinical
models [24,25,46]. Anti-tumor effects of PEP005 have also
been demonstrated in s.c. inoculated melanoma, lung
carcinoma, prostate cancer, cervical carcinoma, and
bladder cancer [46,47]. PEP005 is structurally closely
related to phorbols, and is a potent activator of novel
(δ, ε, η, θ) and classical (α, β, γ) isoenzymes of PKC
at lower concentrations (10 to 100 ng/ml) [48]. However,
PKCδ is the isoform that mediates the pro-apoptotic ef-
fects of PEP005 in myeloid leukemia and colon cancer
cells [23,24,49]. In these cells, PEP005 induces PKCδ
translocation from the cytoplasm to the plasma mem-
brane, nuclear membrane and mitochondrial membrane.
Interestingly, we detected PEP005-induced nuclear
and membrane translocation of PKCδ, PKCα and PKCε
in TRAF3−/− tumor B cells (Figure 5A). In cancer, PKCα
and PKCε are generally linked to proliferation or sur-
vival and thus considered as oncogenes. In contrast,
PKCδ has a pro-apoptotic function in a variety of cancer
cells [22,24,50]. Activation of PKC isoforms signals
further downstream events, such as the activation of p38,
ERK, JNK or NF-κB in melanoma, myeloid leukemia and
colon cancer cells [25,27,35,50,51], which were all observed
in our study of tumor B cells. In colon cancer cells, inhib-
ition of Akt phosphorylation via a PKC-independent mech-
anism also contributes to the apoptotic effects of PEP005
[24,49]. In contrast, we found that PEP005 induced Akt
phosphorylation in TRAF3−/− tumor B cells. Therefore, the
ultimate effect of cell proliferation or apoptosis induction
by PEP005 depends on the balance between the levels and
activities of pro-apoptotic (PKCδ) and anti-apoptotic (PKCα
and PKCε) isoforms of PKC as well as their crosstalk with
different signaling pathways (MAPKs, NF-κB, and Akt) in
each tumor B cell line. Indeed, we detected varying levels of
different PKC isoforms (α, δ and ε) in different tumor
B cell lines, and this may contribute to the observed
divergent responses of the cells to PEP005. Our find-
ings thus provide new insights into the complexity of
the signaling pathways controlled by PEP005 in
TRAF3−/− tumor B cells.
N-Benzyladriamycin-14-valerate (AD 198) is a novel
semisynthetic, lipophilic anthracycline analogue with
experimental anti-tumor activity superior to that of
doxorubicin (DOX) [22,34,52]. Nuclear-targeted anth-
racycline antibiotics, such as DOX, are known to
exert their anti-tumor effects primarily via DNA
intercalation and topoisomerase II inhibition, thereby
causing double-stranded DNA breaks and promoting
apoptosis. The extranuclear-targeted AD 198, unlike
DOX, only weakly binds DNA, and does not inhibit
topoisomerase II [22,34,52,53]. AD 198 is structurally
similar to commonly accepted ligands for the C1 regula-
tory domain of PKC, and binds to the diacylglycerol-binding C1b domain of classical and novel PKC isoforms
[38,52,54]. The interaction between AD 198 and the C1b
domain leads to the activation of PKC isoforms, especially
PKCδ, and thereby promoting rapid apoptosis in a variety
of cancer cells, including myeloid leukemia, breast cancer,
prostate cancer, melanoma, colon cancer, and ovarian
carcinoma [20,22,38,54]. PKCδ was identified as the
principal target of AD 198 that mediates the apoptotic
effects of AD 198 [20,22,53].
In myeloid leukemia cells, AD 198 induces the
mitochondrial and membrane translocation of PKCδ,
PKCα and PKCε [20,21,38,53]. In the present study,
we found that AD 198 induced caspase 3 activation, PKCδ
cleavage, and DNA fragmentation in TRAF3−/− tumor B
cells as previously observed in myeloid leukemia cells.
However, AD 198-induced apoptosis of tumor B cells was
not mediated through the activation of PKCδ, as trans-
location or phosphorylation of PKCδ was not detected.
Additionally, translocation of PKCα or PKCε was not
induced by AD 198 in tumor B cells either. Thus, the
anti-proliferative and apoptosis-inducing effects of AD
198 on TRAF3−/− tumor B cells are mediated through
a novel, PKCδ-independent mechanism.
We identified c-Myc as the principal target of AD 198
in TRAF3−/− and TRAF3-sufficient malignant B cells. We
found that both the mRNA and protein levels of c-Myc
were strikingly and rapidly suppressed by AD 198. In
support of the important role of c-Myc down-regulation,
we observed that lentiviral vector-mediated constitutive
expression of c-Myc conferred robust resistance to the
anti-proliferative/survival-inhibitory effects of AD 198 in
human MM cells. The c-Myc protein is a central regulator
of B cell survival and proliferation, and has a short half-
life (about 20–30 minutes) [55,56]. It has been previously
shown that the promoter regions of both human and
mouse c-Myc genes contain binding sites for AP-1, a
transcription factor directly activated by ERK, p38
and JNK signaling pathways [42-44]. AP-1 is also indirectly
inhibited by Akt activity [42]. Interestingly, we found that
AD 198 inhibited ERK, p38 and JNK activation, but
promoted Akt activation in TRAF3−/− tumor B cells.
In this context, our results suggest that AD 198 targets
c-Myc by inhibiting c-Myc transcription in tumor B cells,
which is mediated through inhibition of ERK, p38 and
JNK pathways as well as activation of the Akt pathway.
However, we could not exclude additional mecha-
nisms, as it has been shown that AD 198 inhibits E. coli
RNA polymerase or chicken leukemic RNA polymerase
activity through drug-template interaction or enzyme
inactivation, respectively [57]. Regardless of the exact
mechanisms, given that elevated expression of c-Myc
is ubiquitously observed in many B cell malignancies
[45], our findings suggest that AD 198 may have wide
therapeutic application in B cell neoplasms.
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superior to DOX in breast cancer, ovarian carcinoma
and melanoma models [36,58], which was recapitulated
in our TRAF3−/− mouse B lymphomas. We previously
showed that DOX did not exhibit tumoricidal activity on
primary B lymphoma cells derived from B-TRAF3−/− mice
[14]. Here we report that AD 198 has potent anti-tumor
effects on TRAF3−/− mouse B lymphomas and human
MM. AD 198 can also override multiple mechanisms of
DOX resistance, including those mediated by p53 dysfunc-
tion, or by overexpression of the multidrug trans-
porters (P-glycoprotein and multidrug resistance protein)
or the anti-apoptotic proteins (Bcl-2, Bcl-xL and NF-κB)
[20,38,53,59]. Importantly, AD 198 is also pharmacologically
superior to DOX in terms of its decreased cardiotoxicity,
low hematotoxicity, and the rapid rate of intracellular
uptake [33-36]. The use of DOX is limited by its
dose-dependent, and often irreversible cardiotoxicity.
However, AD 198 does not exhibit significant cardiotoxicity
or other organ toxicities at therapeutic doses, and is
cardioprotective in rodent models [33-36]. In support of
this notion, we demonstrated that in NOD SCID mice
transplanted with TRAF3−/− mouse B lymphomas, adminis-
tration of AD 198 drastically extended the survival of mice
and inhibited the growth and metastasis of B lymphomas.
In fact, AD 198 demonstrated a higher in vivo potency than
oridonin, an inhibitor of both NF-κB2 and NF-κB1 path-
ways [14]. In summary, our findings reveal a novel PKCδ-
independent mechanism of AD 198 that targets c-Myc in
malignant B cells, and support further clinical studies of
AD 198 as an anti-cancer agent for NHL and MM.
Conclusions
In the present study, we have uncovered a novel, PKCδ-
independent mechanism of the anti-tumor effects of AD
198 that strikingly targets c-Myc in TRAF3−/− tumor B
cells. AD 198-induced signaling events appear to occur
in the following order: AD 198 treatment → diminished
phosphorylation of ERK1/2 and p38 but increased
Akt phosphorylation (5 minutes) → down-regulation
of c-Myc transcription (10–30 minutes) → decreased
protein levels of c-Myc (1 hour) → caspase 3 activation
(3 hours) → cleavage of PKCδ (6 hours) → DNA
fragmentation and apoptosis (6–24 hours). In contrast,
PEP005 activates multiple signaling pathways in these
cells, including PKCδ, PKCα, PKCε, NF-κB1, ERK, JNK,
and Akt. Furthermore, we extended the investigation of
AD 198 to TRAF3-sufficient malignant B cells, and found
that AD198 also exhibits anti-tumor activity and potently
suppresses c-Myc expression in TRAF3-sufficient mouse
and human B lymphoma cell lines. Taken together, our
findings suggest that AD 198 has therapeutic potential
for the treatment of NHL and MM involving TRAF3
inactivation or c-Myc up-regulation.Additional file
Additional file 1: Figure S1. PEP005 exhibited differential effects on
TRAF3−/− mouse B lymphoma and human MM cells. Total viable cell
numbers were determined by MTT assay at 24 h after PEP005
treatment. (A and B) Effects on primary splenic B lymphoma cells
harvested from diseased B-TRAF3−/− mice. Similar results were also
obtained with primary B lymphoma cells purified from ascites, cervical
and mesenteric LNs of several individual B-TRAF3−/− mice with tumors.
(C) Effects on TRAF3−/− mouse B lymphoma cell lines. (D) Effects on
human MM cell lines. The graphs depict the results of three indepen-
dent experiments with duplicate samples in each experiment (mean ±
SEM). Figure S2. PEP005 did not induce apoptosis in TRAF3−/− tumor B
cells. Cell cycle distribution was determined by PI staining and flow
cytometry. TRAF3−/− mouse B lymphoma cell lines (A) or human MM
cell lines (B) were cultured in the absence or presence of PEP005 of
indicated concentration for 24 h before PI staining. Representative
histograms of PI staining are shown, and percentage of apoptotic cells
(DNA content < 2n) and proliferating cells (2n < DNA content ≤ 4n)
are indicated. Results are representative of three independent experi-
ments. Figure S3. Effects of PEP005 on the cytosolic and nuclear levels
of PKCδ, NF-κB1 and NF-κB2 subunits, and c-Myc. (A) Dose-dependent
effects of PEP005. Mouse or human tumor B cells were cultured with
various concentrations of PEP005 for 6 h. (B) Time-dependent effects of
PEP005. Mouse or human tumor B cells were cultured in the absence
or presence of PEP005 for indicated time periods. Cytosolic and nuclear
extracts were prepared as described in the Methods. Proteins were
immunoblotted for PKCδ, NF-κB2 (p100 – p52), RelB, NF-κB1 c-Rel, RelA,
c-Myc, followed by HDAC1 and actin. Results are representative of
three independent experiments. Similar results were also obtained with
other TRAF3−/− cell lines.Abbreviations
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